Description:
Tirzepatide is a dual GIP and GLP-1 receptor agonist peptide under investigation for its potent effects on glycemic control and weight management. Clinical studies have demonstrated its superior efficacy compared to existing GLP-1 receptor agonists.
Research Application: (SubQ, once weekly):
Week 1–4: 2.5 mg
Week 5–8: 5 mg
Week 9–12: 10 mg
Week 13+: 15 mg
Research Highlights:
HbA1c reductions up to 2.58%
Body weight loss up to 20.9%
Improved cardiovascular and renal outcomes
Availability:
Purity: ≥99%
Form: Lyophilized powder for reconstitution
Disclaimer:
The statements made on this website have not been evaluated by the US Food and Drug Administration. These are not findings from Raina's Summit, but instead publicly available studies. This product is for research purposes only.
Tirzepatide (5mg-75mg)
C₂₂₅H₃₄₈N₄₈O₆₈
At Raina's Summit, we are committed to providing research compounds of the highest standard—we perform quality batch testing to verify each product meets a minimum purity of 99% or we guarantee your money back.